SF 3676

as introduced - 84th Legislature (2005 - 2006) Posted on 12/15/2009 12:00am

A bill for an act
relating to health; requiring the commissioner of health to conduct a study to
determine the extent of prenatal drug exposure in babies born in Minnesota.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

Section 1. new text begin STUDY ON PRENATAL DRUG EXPOSURE.
new text end

new text begin (a) The commissioner of health, in consultation with the University of Minnesota
Department of Epidemiology and the Minnesota Hospital Association, shall conduct a
study by collecting and analyzing data to determine the prevalence of prenatal illicit
drug exposure in order to assist the legislature in directing resources to address early
intervention and the special needs of these infants. The study shall involve obtaining the
information described in paragraph (c) and testing specimens of the meconium of at least
3,000 infants born in Minnesota.
new text end

new text begin (b) The commissioner, in consultation with the Minnesota Hospital Association,
shall identify no less than three hospitals with at least one of the hospitals located outside
the seven-county metropolitan area to participate in the study. The participating hospitals
shall collect a meconium specimen from a specified number of randomly selected infants
who are born at the participating hospital during the period of time identified in the study.
The specimen shall be processed at a laboratory specified by the commissioner for the
presence of methamphetamine, cocaine, morphine and morphine derivatives, and THC.
new text end

new text begin (c) In addition to the specimen collection, the participating hospital shall collect and
submit to the commissioner the following information for each of the randomly selected
births:
new text end

new text begin (1) maternal demographics, including age, marital status, and county of residence;
new text end

new text begin (2) any maternal complications, including placental abruption, preterm labor, or
preeclampsia;
new text end

new text begin (3) birth weight;
new text end

new text begin (4) gestational age;
new text end

new text begin (5) admission of the infant to a neonatal intensive care unit;
new text end

new text begin (6) preterm labor;
new text end

new text begin (7) infant complications, including a low Apgar score or birth defects; and
new text end

new text begin (8) any maternal report of illicit drug usage during pregnancy.
new text end

new text begin (d) The commissioner shall analyze the information received from the participating
hospitals and the processed specimens to determine:
new text end

new text begin (1) the incidence of prenatal drug exposure by:
new text end

new text begin (i) drug;
new text end

new text begin (ii) hospital; and
new text end

new text begin (iii) county of residence;
new text end

new text begin (2) any association of preterm or low birth weight deliveries with prenatal drug
exposure;
new text end

new text begin (3) any association of maternal complications with prenatal drug exposure; and
new text end

new text begin (4) a comparison of reported maternal drug usage with the results of the specimen
collected.
new text end

new text begin (e) Data submitted to the commissioner must not contain any patient-identifying
information. The commissioner shall provide the participating hospitals with a coded
study number to be used to match the infant meconium specimens collected with the
other information described in paragraph (c). Data submitted to the commissioner under
this section are private data on individuals or nonpublic data as defined in Minnesota
Statutes, section 13.02.
new text end

new text begin (f) The commissioner shall submit a report of the findings of the study indicating the
prevalence of prenatal drug exposure to the legislature by September 15, 2007.
new text end

Sec. 2. new text begin APPROPRIATION.
new text end

new text begin $....... is appropriated in fiscal year 2007 from the health care access fund to the
commissioner of health to conduct the prenatal drug exposure study.
new text end